Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 14 January 2026 - 21 January 2026

ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update

ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update

New York, January 21, 2026, 14:23 ET — Regular session ImmunityBio shares dropped roughly 2% to $6.35 in Wednesday afternoon trading, as investors pared back after the biotech’s recent regulatory update. The stock swung between $5.74 and $6.64, with around 67 million shares changing hands. The pullback is significant since the stock’s trajectory hinges on one key factor: how soon…
21 January 2026
·····
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

New York, January 21, 2026, 05:35 ET — Premarket Shares of Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) dropped nearly 8%, slipping to $19.68 in premarket trading Wednesday. The decline follows the company’s announcement of an underwritten public offering worth $150 million in common stock and pre-funded warrants. These warrants let investors lock in shares now by paying most of the price…
21 January 2026
·····
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

New York, January 20, 2026, 14:02 EST — Regular session Merck & Co (MRK.N) shares held steady on Tuesday following news that the company’s personalized cancer vaccine, developed with Moderna, continued to lower the risk of melanoma recurrence and death when used alongside Keytruda (pembrolizumab). By 2:02 p.m. EST, Merck was down just 0.01% at $108.82, with the stock fluctuating…
20 January 2026
·····
Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk

Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk

New York, January 20, 2026, 12:33 EST — Regular session Qiagen’s shares in the U.S. surged 15.9% to $55.13 on Tuesday after reports surfaced that the molecular diagnostics firm is exploring strategic options, including a potential sale, amid renewed takeover interest. The term often signals major moves like a sale; Qiagen has yet to comment. (Reuters) This report is significant…
20 January 2026
····
ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

New York, January 20, 2026, 08:14 (EST) — Premarket ImmunityBio (IBRX.O) shares rose about 27% to $7 in premarket trading on Tuesday, with about 4.1 million shares changing hands, after the company said it had made progress with the U.S. Food and Drug Administration on a path to revive a label-expansion push for its bladder cancer treatment ANKTIVA. (Public) The…
20 January 2026
·····
ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

New York, Jan 17, 2026, 08:04 ET — Market closed. ImmunityBio shares jumped on Friday and look set to remain in the spotlight when U.S. markets open again. The company revealed a steep rise in preliminary sales for its bladder cancer immunotherapy ANKTIVA, alongside a quicker-than-anticipated pace in trial enrollments. (Nasdaq) Why this matters now: these updates offer traders new…
17 January 2026
·····
Thermo Fisher Scientific stock slips into long weekend as TMO traders eye Jan. 29 earnings

Thermo Fisher Scientific stock slips into long weekend as TMO traders eye Jan. 29 earnings

New York, Jan 16, 2026, 19:36 ET — After-hours Thermo Fisher Scientific shares dipped 0.9% to close at $618.72 on Friday, then stayed close to that price in after-hours trading. During the day, the stock fluctuated between $618.20 and $629.50. Trading volume hit roughly 2.9 million shares, matching its typical daily activity. The pullback arrives as investors await Thermo Fisher’s…
17 January 2026
·····
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

New York, Jan 16, 2026, 14:14 ET — Regular session AbbVie Inc shares dropped 1.1% to $214.35 Friday afternoon after releasing mixed results from a late-stage trial of its lymphoma drug epcoritamab. The Phase 3 study hit its primary endpoint, showing improved progression-free survival — meaning patients lived longer without their cancer worsening — but it missed a statistically significant…
16 January 2026
·····
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

New York, Jan 16, 2026, 12:51 PM EST — Regular session ImmunityBio (IBRX.O) shares jumped about 35% on Friday after the cancer drugmaker reported faster enrollment and stronger interim results in a key bladder cancer study for its ANKTIVA therapy. The stock was up $1.39 at $5.34 by 12:51 p.m. EST after hitting $5.53, with about 133 million shares traded.…
16 January 2026
·····
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

New York, Jan 16, 2026, 10:16 EST — Regular session ImmunityBio shares surged roughly 16.5% to $4.60 Friday morning, building on a strong rally after the biotech reported better-than-expected sales momentum for its main cancer drug. The company also detailed plans for a label-expansion effort. Trading volume exceeded 56 million shares, with the stock reaching an intraday peak of $5.20.…
16 January 2026
·····
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

New York, January 14, 2026, 14:14 EST — Regular session Viridian Therapeutics shares climbed 6.4% to $34.03 in early afternoon trading on Wednesday, after hitting an intraday high of $34.25, a new 52-week peak. The gain bucked a softer market. The Invesco QQQ Trust, a proxy for the Nasdaq 100, was down about 1.5%, while the SPDR S&P 500 ETF…
14 January 2026
·····
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

New York, Jan 14, 2026, 12:57 EST — Regular session Terns Pharmaceuticals (TERN.O) shares jumped over 10% Wednesday, fueled by the company’s newest conference update on its lead cancer drug. By midday, the stock had risen 10.4% to $38.03, after trading in a range from $34.05 to $38.35. The shift coincides with biotech investors flocking to the annual J.P. Morgan…
14 January 2026
·····
1 2 3 4 5 … 24

Stock Market Today

  • Jardine Matheson Holdings Repurchases 100,700 Shares at Average Price of $73.64
    February 2, 2026, 7:02 AM EST. Jardine Matheson Holdings Ltd (JMH) repurchased 100,700 of its ordinary shares on February 2, 2026. The shares were bought back at prices ranging from $73.465 to $73.7327 per share, with a weighted average price of $73.6397. Following cancellation of these shares, JMH's issued share capital now stands at 294,404,878 ordinary shares, each with one voting right. JMH holds no treasury shares. This transaction reflects JMH's ongoing capital management strategy and complies with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The share buyback reduces the total shares outstanding, potentially impacting shareholder value and voting power.
Go toTop